Biohealth Innovation

Click here to view original article »

Trouble Viewing This Email: Click Here

July 6, 2022

FOUNDING MEMBER OF

2022 Crab Trap Application

Crab Trap 2022 applications are being accepted through August 31st! Entrepreneurs with innovative diagnostics, medical devices, therapeutics, or other transformative health solutions are invited to apply to the 7th annual BioHealth Capital Region Crab Trap pitch competition. Finalists for the 2022 Crab Trap competition will pitch IN PERSON on September 21st as part of the BioHealth Capital Region Investor Conference. The winning teams will receive cash prizes from our sponsors.

Applications are due by 5pm on Wednesday, August 31st. Crab Trap finalists will be notified the week of 9/5/22. Mandatory virtual pitch coaching for all finalists will take place the week of 9/12/22.

NIH/BHI Seeks Life Science Business Analyst

BioHealth Innovation, Inc. (BHI), is a Montgomery County innovation intermediary which translates market-relevant research into commercial success by bringing together management, funding, and markets. BHI is seeking a life science business analyst to support the NIH SEED Office (https://seed.nih.gov/). The analyst will provide business landscape analysis and other project support on product development, corporate strategy, and private investment for NIH-funded companies. This will entail market landscape, technology, and other business intelligence research to support Entrepreneur-in-Residence and other SEED life science commercialization activities.

Click here for more information.

BioHealth Innovation is seeking a Senior Life Sciences Business Strategist

BioHealth Innovation, Inc., (BHI) is a regional non-profit innovation intermediary, which facilitates the development of growth-stage biohealth companies by connecting commercially relevant research assets to appropriate funding, management and markets.

JOB TITLE – Senior Life Sciences Business Strategist

Reporting to the Vice President of Economic Development, the Senior Life Sciences Business Strategist evaluates the commercial potential of emerging technologies and provides recommendations on go-to- market strategies. This is a customer facing role with a focus on supporting clients in the development of commercial analyses and federal grant proposals.

The Senior Life Sciences Business Strategist also supervises junior Life Sciences Business Strategists and manages consultants and interns, as needed.

Click here to download a PDF with the details.

How can your BioHealth business benefit from a review by BHI industry experts? Please register for our next Entrepreneur-In-Residence (EIR) day on July 20th and find out. To sign-up for any of the EIR dates in 2022, please follow this link.

These free 1:1 virtual sessions are an opportunity to discuss your company with experts in diagnostics, therapeutics, digital health and medical devices. If you’re a growth-stage biohealth company looking for unbiased advice on your pitch deck, commercialization strategy, evidence development or entrepreneurial challenges, our EIRs can help.

To sign-up for any of the EIR dates in 2022, please follow this link.

Maryland Inno - TEDCO seeks firm to provide recommendations on creating possible $500M fund

The Maryland Technology Development Corp. is searching for a firm to assess Maryland’s current economic development strategy and make recommendations to help shape the creation of a possible $500 million fund.

TEDCO issued a request for proposal (RFP) for firms to conduct the study earlier this week. The research will be used by TEDCO to help create draft legislation for the Maryland Equitech Growth Fund, which has a recommended minimum of $500 million worth of public investment over a 10-year period. The study is being done at the behest of the Maryland legislature, which called on TEDCO to create the report.

Image: TEDCO, led by CEO Troy LeMaile-Stovall, is searching for a firm to assess Maryland's current economic development strategy. TEDCO

AMPEL BioSolutions' Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning

AMPEL BioSolutions' Precision Medicine Breakthrough AMPEL BioSolutions' Precision Medicine Breakthrough Predicts Drug Options with RNA Analytics & Machine Learning CHARLOTTESVILLE, Va., July 6, 2022 -- AMPEL BioSolutions today announces a breakthrough in precision and personalized medicine that could modernize the way doctors treat patients across a wide variety of diseases including autoimmunity, infectious disease and cancer. Revealed at the Precision Medicine World Conference in Silicon Valley California, the first-in-class platform technology utilizes RNA analytics and machine learning to characterize an individual’s gene expression and provide clinical decision support to physicians for treatment options for their patients. The technology, only a concept for the last few years, is being utilized to launch a portfolio of 10+ clinical tests over the next five years to provide decision support for diseases that affect more than 50 million Americans.